FORAGER-1: A Phase 1, Open-Label, Multicenter Study of LOXO-435 (LY3866288) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer With FGFR3 Alterations
Latest Information Update: 24 Apr 2025
At a glance
- Drugs LOXO 435 (Primary) ; Enfortumab vedotin; Pembrolizumab
- Indications Carcinoma; Solid tumours; Urogenital cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms FORAGER-1
- Sponsors Eli Lilly and Company
Most Recent Events
- 17 Apr 2025 Planned End Date changed from 1 Jun 2025 to 1 Jun 2027.
- 17 Apr 2025 Planned primary completion date changed from 1 Jun 2025 to 1 Jun 2027.
- 08 Apr 2025 Protocol has been amended to add cohorts in combination with Enfortumab Vedotin. Number of patients increased. Cohort A2 randomized.